These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16448223)

  • 21. Association of BRCA2 K3326* With Small Cell Lung Cancer and Squamous Cell Cancer of the Skin.
    Rafnar T; Sigurjonsdottir GR; Stacey SN; Halldorsson G; Sulem P; Pardo LM; Helgason H; Sigurdsson ST; Gudjonsson T; Tryggvadottir L; Olafsdottir GH; Jonasson JG; Alexiusdottir K; Sigurdsson A; Gudmundsson J; Saemundsdottir J; Sigurdsson JK; Johannsdottir H; Uitterlinden A; Vermeulen SH; Galesloot TE; Allain DC; Lacko M; Sigurgeirsson B; Thorisdottir K; Johannsson OT; Sigurdsson F; Ragnarsson GB; Isaksson H; Hardardottir H; Gudbjartsson T; Gudbjartsson DF; Masson G; Kiemeney LAML; Ewart Toland A; Nijsten T; Peters WHM; Olafsson JH; Jonsson S; Thorsteinsdottir U; Thorleifsson G; Stefansson K
    J Natl Cancer Inst; 2018 Sep; 110(9):967-974. PubMed ID: 29767749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients.
    Johannesdottir G; Gudmundsson J; Bergthorsson JT; Arason A; Agnarsson BA; Eiriksdottir G; Johannsson OT; Borg A; Ingvarsson S; Easton DF; Egilsson V; Barkardottir RB
    Cancer Res; 1996 Aug; 56(16):3663-5. PubMed ID: 8706004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
    Tryggvadottir L; Olafsdottir EJ; Olafsdottir GH; Sigurdsson H; Johannsson OT; Bjorgvinsson E; Alexiusdottir K; Stefansson OA; Agnarsson BA; Narod SA; Eyfjord JE; Jonasson JG
    Breast Cancer Res Treat; 2013 Jul; 140(2):375-84. PubMed ID: 23857704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer.
    Sigbjörnsdottir BI; Ragnarsson G; Agnarsson BA; Huiping C; Barkardottir RB; Egilsson V; Ingvarsson S
    J Med Genet; 2000 May; 37(5):342-7. PubMed ID: 10807692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutation.
    Ingvarsson S; Geirsdottir EK; Johannesdottir G; Sigbjörnsdóttir BI; Eiriksdottir G; Ragnarsson G; Agnarsson BA; Gudmundsson J; Jonasson JG; Sigurdsson A; Egilsson V; Barkardottir RB
    Cancer Res; 1998 Oct; 58(19):4421-5. PubMed ID: 9766673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromosomal mutagen sensitivity associated with mutations in BRCA genes.
    Speit G; Trenz K
    Cytogenet Genome Res; 2004; 104(1-4):325-32. PubMed ID: 15162060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
    Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
    Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub-population.
    Pääkkönen K; Sauramo S; Sarantaus L; Vahteristo P; Hartikainen A; Vehmanen P; Ignatius J; Ollikainen V; Kääriäinen H; Vauramo E; Nevanlinna H; Krahe R; Holli K; Kere J
    Genet Epidemiol; 2001 Feb; 20(2):239-46. PubMed ID: 11180449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
    Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN
    BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population-based study of risk of breast cancer in carriers of BRCA2 mutation.
    Thorlacius S; Struewing JP; Hartge P; Olafsdottir GH; Sigvaldason H; Tryggvadottir L; Wacholder S; Tulinius H; Eyfjörd JE
    Lancet; 1998 Oct; 352(9137):1337-9. PubMed ID: 9802270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers.
    De Brakeleer S; Bogdani M; De Grève J; Decock J; Sermijn E; Bonduelle M; Goelen G; Teugels E
    Mutat Res; 2007 Jun; 619(1-2):104-12. PubMed ID: 17445839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
    Verhoog LC; van den Ouweland AM; Berns E; van Veghel-Plandsoen MM; van Staveren IL; Wagner A; Bartels CC; Tilanus-Linthorst MM; Devilee P; Seynaeve C; Halley DJ; Niermeijer MF; Klijn JG; Meijers-Heijboer H
    Eur J Cancer; 2001 Nov; 37(16):2082-90. PubMed ID: 11597388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations.
    Martínez-Ferrandis JI; Vega A; Chirivella I; Marín-García P; Insa A; Lluch A; Carracedo A; Chaves FJ; García-Conde J; Cervantes A; Armengod ME
    Hum Mutat; 2003 Nov; 22(5):417-8. PubMed ID: 14517958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas.
    Akbari MR; Donenberg T; Lunn J; Curling D; Turnquest T; Krill-Jackson E; Zhang S; Narod SA; Hurley J
    Clin Genet; 2014 Jan; 85(1):64-7. PubMed ID: 23458327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aurora-A amplification associated with BRCA2 mutation in breast tumours.
    Bodvarsdottir SK; Hilmarsdottir H; Birgisdottir V; Steinarsdottir M; Jonasson JG; Eyfjord JE
    Cancer Lett; 2007 Apr; 248(1):96-102. PubMed ID: 16860930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.
    Peixoto A; Salgueiro N; Santos C; Varzim G; Rocha P; Soares MJ; Pereira D; Rodrigues H; Bento MJ; Fráguas A; Moura G; Regateiro F; Castedo S; Teixeira MR
    Fam Cancer; 2006; 5(4):379-87. PubMed ID: 16826315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
    Jonasson JG; Stefansson OA; Johannsson OT; Sigurdsson H; Agnarsson BA; Olafsdottir GH; Alexiusdottir KK; Stefansdottir H; Munoz Mitev R; Olafsdottir K; Olafsdottir K; Arason A; Stefansdottir V; Olafsdottir EJ; Barkardottir RB; Eyfjord JE; Narod SA; Tryggvadóttir L
    Br J Cancer; 2016 Sep; 115(7):776-83. PubMed ID: 27537391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
    Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
    J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation analysis of BRCA1 and BRCA2 genes in Iranian high risk breast cancer families.
    Pietschmann A; Mehdipour P; Mehdipour P; Atri M; Hofmann W; Hosseini-Asl SS; Scherneck S; Mundlos S; Peters H
    J Cancer Res Clin Oncol; 2005 Aug; 131(8):552-8. PubMed ID: 15918047
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.